Resources from the same session
1619O - High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA67 - TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas
Presenter: Maud Toulmonde
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA68 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER
Presenter: Florence Duffaud
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
1620O - Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma
Presenter: Joseph Ludwig
Session: Proffered Paper - Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant 1619O and LBA67
Presenter: Javier Martin Broto
Session: Proffered Paper - Sarcoma
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Winette Van Der Graaf
Session: Proffered Paper - Sarcoma
Resources:
Webcast
Invited Discussant LBA68 and 1620O
Presenter: Sandra Strauss
Session: Proffered Paper - Sarcoma
Resources:
Slides
Webcast